which will be held in Orlando, Florida, and virtually on December 1-3, 2021.
MENLO PARK, Calif., June 9, 2021 /PRNewswire/ -- LIPAC Oncology LLC., a pharmaceutical company utilizing its next generation precision liposomal technology to locally deliver taxanes to target tissues, today announced the positive results from the two-year follow-up for TD-001, its Phase 1/2a study of LiPax in patients with non-muscle invasive bladder cancer (NMIBC) who have undergone transurethral resection of bladder tumor (TURBT). Results demonstrate a recurrence free survival (RFS) rate of 83% compared to 49% for current standard of care therapies.
MENLO PARK, Calif., April 29, 2021 /PRNewswire/ -- LIPAC Oncology LLC today announced the conclusion of a successful Type B meeting with the U.S. Food and Drug Administration (FDA) to discuss Phase 2b/3 clinical trials of LiPax in patients with low-grade highly recurrent non-muscle invasive bladder cancer (NMIBC). The feedback from the FDA provides a clear path for LIPAC Oncology to initiate the Phase 2b trial for LiPax in the second half of 2021.
MENLO PARK, Calif. and SEOUL, Korea, Dec. 10, 2020 /PRNewswire/ -- LIPAC Oncology LLC and Huons Co., Ltd. today announced the achievement of a major development milestone in their partnering agreement by finalizing its Clinical Study Report for a Phase 2A marker lesion clinical trial in patients with low-grade highly recurrent Non-Muscle Invasive Bladder Cancer (NMIBC) treated with LiPax (paclitaxel). LiPax, a proliposomal paclitaxel formulation in development for intravesical instillation in the treatment of NMIBC, demonstrated a 63 percent responder rate in highly recurrent and heavily pre-treated patients.
LIPAC Oncology LLC today announced the successful completion of a Phase 2A marker lesion clinical trial designed to predict long-term (two-year) recurrence free survival rates in patients with low-grade highly recurrent Non-Muscle Invasive Bladder Cancer (NMIBC)Â treated with LiPax